Susan Galbraith, AstraZeneca EVP, oncology R&D
October 26, 2022 07:33 AM EDTUpdated 09:39 AM
R&D

As­traZeneca spot­lights pos­i­tive PhII, PhI­II read­out for a pair of next-gen breast can­cer drugs

Amber Tong

Two decades af­ter the FDA first ap­proved ful­ves­trant to treat a type of breast can­cer, As­traZeneca says it has gar­nered da­ta that could ush­er in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times